E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute right ventricular failure. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 7.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054933 |
E.1.2 | Term | <Manually entered code. Term in E.1.1> |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the trial is to assess the utility of nitric oxide for inhalation for the management of acute right ventricular failure during LVAD placement.
Left ventricular assist device- LVAD
|
|
E.2.2 | Secondary objectives of the trial |
The secondary study objectives are:
- to assess the safety of nitric oxide for inhalation in this patient population. - to assess the effect of nitric oxide for inhalation on the number of intensive care unit (ICU) and total hospital days from date of surgery to discharge date. - to assess the effect of nitric oxide for inhalation on length of time on mechanical ventilator. - to assess the effect of nitric oxide for inhalation on survival assessed at 28 days. - to assess the effect of nitric oxide for inhalation on the usage blood products. - to assess need for renal replacement therapies (hemodialysis, artrio-venous or veno-venous hemofiltration) by day 28. -to assess number of patients requiring right ventricular assist device by day 28. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The expected study population will include patients undergoing left vetricular assist device (LVAD) implantation.
Inclusion Criteria: -scheduled to undergo their first LVAD implantation, (or at least 6 months after explantation of a previous LVAD). - has a pulmonary vascular resistance of at least 2.5 Wood units (200 dynes/second) in the 30 days prior to LVAD placement. - greater than 18 years of age. - signed IRB approved informed consent. |
|
E.4 | Principal exclusion criteria |
- patients with congestive heart failure due to giant cell myocarditis or restrictive cardiomyopathy. - Elective Biventricular Assist Device (BiVAD) surgery, or current support with a temporary BiVAD. - LVAD procedure expected to be done without cardiopulmonary bypass. - pregnancy (a negative pregnancy test must be documented prior to enrollment). - received nitric oxide by inhalation therapy within the past 24 hours. - investigational drugs that are expected to change systemic or pulmonary vascular resistance are not allowed. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint for this study will be the number of patients meeting failure criteria within 48 hours on study drug as defined by either 2 or more of the following, sustained for 15 minutes after complete removal from CPB support: - Left ventricular Flow Rate Index (LVFRI) ≤ 2.0 L/min/m2. - Administration of ≥ 20 inotropic equivalents (IE) 10 µg/kg/min dopamine, dobutamine, enoximone or amrinone is equivalent to 10 IE 0.1 µg/kg/min epinephrine or norepinephrine is equivalent to 10 IE 1 µg/kg/min milrinone is equivalent to 15 IE 0.1 U/min vasopressin is equivalent to 10 IE - Mean Arterial Pressure (MAP) ≤ 55 mmHg. - Central Venous Pressure (CVP) ≥ 16 mmHg. - Percent Mixed Venous Oxygen Saturation (SvO2) ≤ 55%.
Or at least one of the following criteria: - Failure to wean from cardiopulmonary bypass at least once due to hemodynamic failure. Re-initiation of cardiopulmonary bypass to correct bleeding or other technical issues will not be considered ‘failure to wean’. - Death.
CPB- Cardiopulmonary Bypass
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |